in force 2023-03-20
02017R0745-20230311 → 02017R0745-20230320
Amended by Regulation (EU) 2023/607 32023R0607
Regulation (EU) 2023/607 of the European Parliament and of the Council of 15 March 2023 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices (Text with EEA relevance)
detected 2026-08-12
3 provisions touched — 3 substantive, 0 date-only, 0 disputed · every change carries an explanation that passed its citation check
MODIFIED +5,504 −517 Art. 120 Transitional provisions§
applies from: unknown (the text changed beyond its dates, so no date that moved can be read as the application date)
dates added to the text: 2023-03-20, 2024-09-26, 2026-05-26, 2027-12-31, 2028-12-31 · dates removed: 2024-05-27, 2025-05-26
The single 2024/2025 sunset dates for certificates and devices under the old paragraphs 2 to 4 are replaced by a more detailed set of risk-class-based deadlines running through 2027 and 2028, together with new conditions on certificate validity and on when manufacturers must have signed agreements or lodged applications with notified bodies.
New paragraphs 3a through 3f are introduced, setting out specific placing-on-the-market deadlines by device class, conditions for extended validity, post-market surveillance rules, surveillance transfer arrangements between notified bodies, and a separate rule for class III custom-made implantable devices.
Paragraph 4 is reworded so that continued availability on the market or putting into service of devices already placed under paragraphs 3, 3a, 3b and 3f is no longer tied to the previously stated end date.
Cited: Art. 120, v1 · Art. 120, v2
text before / after
02017R0745-20230311 → 02017R0745-20230320
Article 120
Transitional provisions
1. From 26 May 2021, any publication of a notification in respect of a notified body in accordance with Directives 90/385/EEC and 93/42/EEC shall become void.
2. Certificates issued by notified bodies in accordance with Directives 90/385/EEC and 93/42/EEC prior to 25 May 2017 shall remain valid until the end of the period indicated on the certificate, except for certificates issued in accordance with Annex 4 to Directive 90/385/EEC or Annex IV to Directive 93/42/EEC which shall become void at the latest on 27 May 2022.
Certificates issued by notified bodies in accordance with Directives 90/385/EEC and 93/42/EEC from 25 May 2017 that were still valid on 26 May 2021 and that have not been withdrawn afterwards shall remain valid until after the end of the period indicated on the certificate until the date set out in paragraph 3a of this Article applicable for the relevant risk class of the devices. Certificates issued by notified bodies in accordance with those Directives from 25 May 2017 that were still valid on 26 May 2021 and that have expired before 20 March 2023 shall be considered to be valid until the dates set out in paragraph 3a of this Article only if one of the following conditions is fulfilled:
(a) before the date of expiry of the certificate, which shall not exceed five years the manufacturer and a notified body have signed a written agreement in accordance with Section 4.3, second subparagraph, of Annex VII to this Regulation for the conformity assessment in respect of the device covered by the expired certificate or in respect of a device intended to substitute that device;
(b) a competent authority of a Member State has granted a derogation from its issuance. They shall however become void at the latest on 27 May 2024. applicable conformity assessment procedure in accordance with Article 59(1) of this Regulation or has required the manufacturer, in accordance with Article 97(1) of this Regulation, to carry out the applicable conformity assessment procedure.
3. By way of derogation from Article 5 and provided the conditions set out in paragraph 3c of this Regulation, Article are met, devices referred to in paragraphs 3a and 3b of this Article may be placed on the market or put into service until the dates set out in those paragraphs.
3a. Devices which have a device which certificate that was issued in accordance with Directive 90/385/EEC or Directive 93/42/EEC and that is a valid by virtue of paragraph 2 of this Article may be placed on the market or put into service until the following dates:
(a) 31 December 2027, for all class III devices, and for class IIb implantable devices except sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors;
(b) 31 December 2028, for class IIb devices other than those covered by point (a) of this paragraph, for class IIa devices, and for class I device devices placed on the market in sterile condition or having a measuring function.
3b. Devices for which the conformity assessment procedure pursuant to Directive 93/42/EEC, 93/42/EEC did not require the involvement of a notified body, for which the declaration of conformity was drawn up prior to 26 May 2021 and for which the conformity assessment procedure pursuant to this Regulation requires the involvement of a notified body, or which has a certificate that was issued in accordance with Directive 90/385/EEC or Directive 93/42/EEC and that is valid by virtue of paragraph 2 of this Article, may be placed on the market or put into service until 26 May 2024, provided that from 26 May 2021 it continues 31 December 2028.
3c. Devices referred to in paragraphs 3a and 3b of this Article may be placed on the market or put into service until the dates referred to in those paragraphs only if the following conditions are met:
(a) those devices continue to comply with either of those Directives, and provided Directive 90/385/EEC or Directive 93/42/EEC, as applicable;
(b) there are no significant changes in the design and intended purpose. However, purpose;
(c) the devices do not present an unacceptable risk to the health or safety of patients, users or other persons, or to other aspects of the protection of public health;
(d) no later than 26 May 2024, the manufacturer has put in place a quality management system in accordance with Article 10(9);
(e) no later than 26 May 2024, the manufacturer or the authorised representative has lodged a formal application with a notified body in accordance with Section 4.3, first subparagraph, of Annex VII for conformity assessment in respect of a device referred to in paragraph 3a or 3b of this Article or in respect of a device intended to substitute that device, and, no later than 26 September 2024, the notified body and the manufacturer have signed a written agreement in accordance with Section 4.3, second subparagraph, of Annex VII.
3d. By way of derogation from paragraph 3 of this Article, the requirements of this Regulation relating to post-market surveillance, market surveillance, vigilance, registration of economic operators and of devices shall apply to devices referred to in paragraphs 3a and 3b of this Article in place of the corresponding requirements in those Directives. Directives 90/385/EEC and 93/42/EEC.
3e. Without prejudice to Chapter IV and paragraph 1 of this Article, the notified body that issued the certificate referred to in the first subparagraph paragraph 3a of this Article shall continue to be responsible for the appropriate surveillance in respect of all of the applicable requirements relating to the devices it has certified. certified, unless the manufacturer has agreed with a notified body designated in accordance with Article 42 that the latter shall carry out such surveillance.
No later than 26 September 2024, the notified body that has signed the written agreement referred to in paragraph 3c, point (e), of this Article shall be responsible for the surveillance in respect of the devices covered by the written agreement. Where the written agreement covers a device intended to substitute a device which has a certificate that was issued in accordance with Directive 90/385/EEC or Directive 93/42/EEC, the surveillance shall be conducted in respect of the device that is being substituted.
The arrangements for the transfer of the surveillance from the notified body that issued the certificate to the notified body designated in accordance with Article 42 shall be clearly defined in an agreement between the manufacturer and the notified body designated in accordance with Article 42 and, where practicable, the notified body that issued the certificate. The notified body designated in accordance with Article 42 shall not be responsible for conformity assessment activities carried out by the notified body that issued the certificate.
3f. By way of derogation from Article 5, class III custom-made implantable devices may be placed on the market or put into service until 26 May 2026 without a certificate issued by a notified body in accordance with the conformity assessment procedure referred to in Article 52(8), second subparagraph, provided that no later than 26 May 2024, the manufacturer or the authorised representative has lodged a formal application with a notified body in accordance with Section 4.3, first subparagraph, of Annex VII for conformity assessment, and, no later than 26 September 2024, the notified body and the manufacturer have signed a written agreement in accordance with Section 4.3, second subparagraph, of Annex VII.
4. Devices lawfully placed on the market pursuant to Directives 90/385/EEC and 93/42/EEC prior to 26 May 2021, and devices lawfully placed on the market from 26 May 2021 pursuant to paragraph 3 paragraphs 3, 3a, 3b and 3f of this Article, may continue to be made available on the market or put into service until 26 May 2025. service.
5. By way of derogation from Directives 90/385/EEC and 93/42/EEC, devices which comply with this Regulation may be placed on the market prior to 26 May 2021.
6. By way of derogation from Directives 90/385/EEC and 93/42/EEC, conformity assessment bodies which … 365 unchanged words … reporting of serious adverse events and device deficiencies shall be carried out in accordance with this Regulation.
12. Until the Commission has designated, pursuant to Article 27(2), issuing entities, GS1, HIBCC and ICCBBA shall be considered to be designated issuing entities.
MODIFIED +43 −32 Art. 122 Repeal§
applies from: unknown (the text changed beyond its dates, so no date that moved can be read as the application date)
dates removed: 2025-05-27
The cross-references to Article 120 have been broadened from paragraphs (3) and (4) to paragraphs (3) to (3e) and (4) in both the opening clause and the paragraph on continued application of the repealed Directives.
The paragraph on continued application of the Directives no longer specifies an end date of 27 May 2025, instead stating that those Directives continue to apply without stating a cut-off date.
That same paragraph also now refers to 'the first paragraph of this Article' rather than simply 'the first paragraph'.
Cited: Art. 122, v1 · Art. 122, v2
text before / after
02017R0745-20230311 → 02017R0745-20230320
Article 122
Repeal
Without prejudice to Articles Article 120(3) to (3e) and (4) of this Regulation, and without prejudice to the obligations of the Member States and manufacturers as regards vigilance and to the obligations of manufacturers as regards the making available of documentation, under Directives 90/385/EEC and 93/42/EEC, those Directives are repealed with effect from 26 May 2021, with the exception of:
Articles 8 and 10, points (b) and (c) of Article 10b(1), Article 10b(2) and Article 10b(3) of Directive 90/385/EEC, and the obligations relating to vigilance and clinical investigations provided for in the corresponding Annexes, which are repealed with effect from the later of the dates referred to in point (d) of Article 123(3) of this Regulation;
Article 10a, point (a) of Article 10b(1) and Article 11(5) of Directive 90/385/EEC, and the obligations relating to registration of devices and economic operators, and to certificate notifications, provided for in the corresponding Annexes, which are repealed with effect from 18 months after the later of the dates referred to in point (d) of Article 123(3) of this Regulation;
Article 10, points (c) and (d) of Article 14a(1), Article 14a(2), Article 14a(3) and Article 15 of Directive 93/42/EEC, and the obligations relating to vigilance and clinical investigations provided for in the corresponding Annexes, which are repealed with effect from the later of the dates referred to in point (d) of Article 123(3) of this Regulation; and
Article 14(1) and (2), points (a) and (b) of Article 14a(1) and Article 16(5) of Directive 93/42/EEC, and the obligations relating to registration of devices and economic operators, and to certificate notifications, provided for in the corresponding Annexes, which are repealed with effect from 18 months after the later of the dates referred to in point (d) of Article 123(3) of this Regulation; and
Article 9(9) of Directive 90/385/EEC and Article 11(13) of Directive 93/42/EEC, which are repealed with effect from 24 April 2020.
As regards the devices referred to in Article 120 (3) 120(3) to (3e) and (4) of this Regulation, the Directives referred to in the first paragraph of this Article shall continue to apply until 27 May 2025 to the extent necessary for the application of those paragraphs.
Notwithstanding the first paragraph, Regulations (EU) No 207/2012 and (EU) No 722/2012 shall remain in force and continue to apply unless and until repealed by implementing acts adopted by the Commission pursuant to this Regulation.
References to the repealed Directives shall be understood as references to this Regulation and shall be read in accordance with the correlation table laid down in Annex XVII to this Regulation.
MODIFIED +8 −55 Art. 123 Entry into force and date of application§
applies from: unchanged
In the list of provisions tied to Eudamed functionality under point (d), the reference to the second sentence of the first subparagraph of Article 120(3) was replaced with a reference to Article 120(3d).
Cited: Art. 123, v2
text before / after
02017R0745-20230311 → 02017R0745-20230320
Article 123
Entry into force and date of application
1. This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
2. It shall apply from 26 May 2021.
3. By way of derogation from paragraph 2:
(a) Articles 35 to 50 shall apply from 26 November 2017. However, from that date until 26 May 2021, the obligations on notified bodies pursuant to Articles 35 to 50 shall apply only to those bodies which submit an application for designation in accordance with Article 38;
(b) Articles 101 and 103 shall apply from 26 November 2017;
(c) Article 102 shall apply from 26 May 2018;
(d) without prejudice to the obligations on the Commission pursuant to Article 34, where, due to circumstances that could not reasonably have been foreseen when drafting the plan referred to in Article 34(1), Eudamed is not fully functional on 26 May 2021, the obligations and requirements that relate to Eudamed shall apply from the date corresponding to six months after the date of publication of the notice referred to in Article 34(3). The provisions referred to in the preceding sentence are:
Article 29,
Article 31,
Article 32,
Article 33(4),
the second sentence of Article 40(2),
Article 42(10),
Article 43(2),
the second subparagraph of Article 44(12),
points (d) and (e) of Article 46(7),
Article 53(2),
Article 54(3),
Article 55(1),
Articles 70 to 77,
paragraphs 1 to 13 of Article 78,
Articles 79 to 82,
Article 86(2),
Articles 87 and 88,
Article 89(5) and (7), and the third subparagraph of Article 89(8),
Article 90,
Article 93(4), (7) and (8),
Article 95(2) and (4),
the last sentence of Article 97(2),
Article 99(4),
the second sentence of the first subparagraph of Article 120(3). 120(3d).
Until Eudamed is fully functional, the corresponding provisions of Directives 90/385/EEC and 93/42/EEC shall continue to apply for the purpose of meeting the obligations laid down in the provisions listed in the first paragraph of this point regarding exchange of information including, and in particular, information regarding vigilance reporting, clinical investigations, registration of devices and economic operators, and certificate notifications.
(e) Article 29(4) and Article 56(5) shall apply from 18 months after the later of the dates referred to in point (d);
(f) for implantable devices and for class III devices Article 27(4) shall apply from 26 May 2021. For class IIa and class IIb devices Article 27(4) shall apply from 26 May 2023. For class I devices Article 27(4) shall apply from 26 May 2025;
(g) with regard to reusable devices that are required to bear the UDI carrier on the device itself, Article 27(4) shall apply to:
(i) implantable devices and class III devices from 26 May 2023;
(ii) class IIa and class IIb devices from 26 May 2025;
(iii) class I devices from 26 May 2027;
(h) The procedure set out in Article 78 shall apply from 26 May 2027, without prejudice to Article 78(14);
(i) Article 120(12) shall apply from 26 May 2019;
(j) Article 59 shall apply from 24 April 2020.
The full entry, with the citation mapping v1 = 02017R0745-20230311, v2 = 02017R0745-20230320, is committed at eu/32017R0745/CHANGELOG.md.